CN1272058A - 多孔微粒及其使用方法 - Google Patents
多孔微粒及其使用方法 Download PDFInfo
- Publication number
- CN1272058A CN1272058A CN98809603A CN98809603A CN1272058A CN 1272058 A CN1272058 A CN 1272058A CN 98809603 A CN98809603 A CN 98809603A CN 98809603 A CN98809603 A CN 98809603A CN 1272058 A CN1272058 A CN 1272058A
- Authority
- CN
- China
- Prior art keywords
- powder
- porous microstructure
- porous
- surfactant
- bioactivator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Abstract
Description
化合物 | 折光指数 |
HFA-134aHFA-227CFC-12CFC-114PFOB甘露醇乙醇正辛烷DMPCPluronic F-68蔗糖羟乙基淀粉氯化钠 | 1.1721.2231.2871.2881.3051.3331.3611.3971.431.431.5381.541.544 |
色甘酸钠MDI | ||||
MMAD(GSD) | 喉部沉积μg | 微小颗粒分数% | 微小颗粒剂量g | |
Intal*,CFC(n=4)(Rhone-Poulenc Rorer)800μg剂量 | 4.7±0.5(1.9±0.06) | 629 | 24.3±2.1 | 202±27 |
喷雾干燥空心多孔粉末,HFA(Alliance)(n=3)300μg剂量 | 3.4±0.2(2.0±0.3) | 97 | 67.3±5.5 | 200±11 |
样品 | 平均尺寸(微米) | 5.4微米下的% | 95%下(微米) |
纯粉末 | 1.2 | 100 | 2.0 |
MDI | 2.4 | 96.0 | 5.1 |
DPI | 1.1 | 100 | 1.8 |
样品 | 平均尺寸(微米) | 5.4微米下的% | 95%下(微米) |
纯粉末 | 1.3 | 100 | 2.1 |
MDI | 2.2 | 98.1 | 4.6 |
DPI | 1.2 | 99.8 | 2.2 |
样品 | MMAD(GSD) | 微小颗粒分数% | 微小颗粒剂量mcg/剂量 |
VentolinRotacaps(n=2) | 7.869(1.6064) | 20 | 15 |
舒喘宁硫酸盐微球(n=3) | 4.822(1.9082) | 63 | 60 |
Claims (61)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6033797P | 1997-09-29 | 1997-09-29 | |
US60/060,337 | 1997-09-29 | ||
US10693298A | 1998-06-29 | 1998-06-29 | |
US09/106,932 | 1998-06-29 | ||
US13384898A | 1998-08-14 | 1998-08-14 | |
US09/133,848 | 1998-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1272058A true CN1272058A (zh) | 2000-11-01 |
CN1169520C CN1169520C (zh) | 2004-10-06 |
Family
ID=27369827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB98809603XA Expired - Lifetime CN1169520C (zh) | 1997-09-29 | 1998-09-29 | 多孔微粒及其使用方法 |
Country Status (28)
Country | Link |
---|---|
EP (4) | EP1019020A1 (zh) |
JP (9) | JP5372306B2 (zh) |
KR (4) | KR100599634B1 (zh) |
CN (1) | CN1169520C (zh) |
AT (3) | ATE239447T1 (zh) |
AU (4) | AU757153B2 (zh) |
BG (1) | BG64816B1 (zh) |
BR (1) | BR9812693A (zh) |
CA (4) | CA2304819C (zh) |
CZ (1) | CZ300758B6 (zh) |
DE (2) | DE69813853T3 (zh) |
DK (2) | DK1019022T4 (zh) |
EA (2) | EA002562B1 (zh) |
EE (1) | EE04628B1 (zh) |
ES (3) | ES2195408T5 (zh) |
HK (1) | HK1031680A1 (zh) |
HR (1) | HRP20000175B1 (zh) |
IL (2) | IL135126A0 (zh) |
IS (1) | IS2154B (zh) |
ME (1) | MEP4108A (zh) |
NO (1) | NO340149B1 (zh) |
NZ (1) | NZ503464A (zh) |
PL (1) | PL195212B1 (zh) |
PT (1) | PT1019022E (zh) |
RS (1) | RS50182B (zh) |
SK (1) | SK285068B6 (zh) |
TR (1) | TR200000819T2 (zh) |
WO (3) | WO1999016422A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104161731A (zh) * | 2013-05-15 | 2014-11-26 | Cj医药健康株式会社 | 连续工艺的微球制备方法及由此制备的微球 |
CN105193773A (zh) * | 2009-05-29 | 2015-12-30 | 珍珠治疗公司 | 活性剂的呼吸递送 |
CN111700883A (zh) * | 2020-07-23 | 2020-09-25 | 深圳大佛药业股份有限公司 | 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺 |
Families Citing this family (230)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
AU757153B2 (en) * | 1997-09-29 | 2003-02-06 | Novartis Ag | Stabilized preparations for use in metered dose inhalers |
US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
GB9727102D0 (en) * | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
WO2000000215A1 (en) * | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
EP1091755A1 (en) * | 1998-06-29 | 2001-04-18 | Alliance Pharmaceutical Corporation | Particulate delivery systems and methods of use |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US6223455B1 (en) † | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
NZ516083A (en) * | 1999-05-27 | 2003-08-29 | Acusphere Inc | Porous drug matrices and methods of manufacture thereof |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
CA2382821A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
WO2001045731A1 (en) | 1999-12-21 | 2001-06-28 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
DE60112902T2 (de) | 2000-02-08 | 2006-06-14 | 3M Innovative Properties Co | Verfahren und kit zum bereitstellen eines beständigen bilds auf einem substrat |
US20010031342A1 (en) | 2000-02-08 | 2001-10-18 | Engle Lori P. | Media for cold image transfer |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
WO2001085136A2 (en) * | 2000-05-10 | 2001-11-15 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
WO2001087277A2 (en) * | 2000-05-15 | 2001-11-22 | Vectura Limited | Method of manufacturing particles |
NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
US7141236B2 (en) | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
DE10064219B9 (de) * | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung |
US20030072717A1 (en) | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
GB0106403D0 (en) * | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
GB0107106D0 (en) * | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
JP2004528339A (ja) * | 2001-04-26 | 2004-09-16 | ネクター セラピューティクス | 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物 |
US7905230B2 (en) | 2001-05-09 | 2011-03-15 | Novartis Ag | Metered dose inhaler with lockout |
EP1389137B1 (en) * | 2001-05-21 | 2006-07-19 | InJet Digital Aerosols Limited | Compositions for protein delivery via the pulmonary route |
US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US6737043B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecula Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US6759029B2 (en) | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
US7078016B2 (en) | 2001-11-21 | 2006-07-18 | Alexza Pharmaceuticals, Inc. | Delivery of caffeine through an inhalation route |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US7540284B2 (en) | 2001-06-20 | 2009-06-02 | Novartis Pharma Ag | Powder aerosolization apparatus and method |
US8337816B2 (en) * | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
EP1446104B2 (en) | 2001-11-01 | 2011-08-03 | Novartis AG | Spray drying methods |
JP2005514393A (ja) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | アミノグリコシドの肺への供給 |
JP4739672B2 (ja) | 2001-12-21 | 2011-08-03 | ネクター セラピューティクス | 湿気のバリアを有するカプセルパッケージ |
JPWO2003077891A1 (ja) * | 2002-03-18 | 2005-07-14 | アステラス製薬株式会社 | 吸入用粉末医薬組成物およびその製造方法 |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
US6941980B2 (en) | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
PE20040134A1 (es) | 2002-07-25 | 2004-03-06 | Pharmacia Corp | Forma de dosificacion de una vez al dia de pramipexol |
AU2003279070A1 (en) * | 2002-09-30 | 2004-04-23 | Acusphere Inc | Sustained release porous microparticles for inhalation |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
WO2004054556A1 (en) * | 2002-12-13 | 2004-07-01 | Adagit | Pharmaceutical porous particles |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
PL378270A1 (pl) * | 2002-12-31 | 2006-03-20 | Nektar Therapeutics | Preparat farmaceutyczny zawierający nierozpuszczalny środek czynny |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
CN100353997C (zh) | 2003-02-28 | 2007-12-12 | 中外制药株式会社 | 稳定的含蛋白质的制剂 |
WO2004087243A1 (ja) | 2003-03-27 | 2004-10-14 | Bioactis Limited | 鼻腔用粉末薬剤施薬装置 |
US8869794B1 (en) | 2003-04-09 | 2014-10-28 | Novartis Pharma Ag | Aerosolization apparatus with capsule puncturing member |
PT1610850E (pt) | 2003-04-09 | 2012-06-15 | Novartis Ag | Dispositivo para gerar um aerossol com protecção da entrada de ar |
SI1615689T1 (sl) | 2003-04-09 | 2016-05-31 | Novartis Ag | Naprava za aerosolizacijo s poravnalnim vodilom za prebadanje kapsule |
ATE520935T1 (de) | 2003-05-21 | 2011-09-15 | Alexza Pharmaceuticals Inc | Verwendung einer schicht aus festem brennstoff, verfahren zum erstellen einer solchen schicht und zugehörige heizvorrichtung |
US7862834B2 (en) | 2003-05-28 | 2011-01-04 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
EP1667659A1 (en) * | 2003-09-30 | 2006-06-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
US7621299B2 (en) | 2003-10-03 | 2009-11-24 | Cabot Corporation | Method and apparatus for filling a vessel with particulate matter |
EP1677738A2 (en) * | 2003-10-31 | 2006-07-12 | Point Biomedical Corporation | Reconstitutable microsphere compositions useful as ultrasonic contrast agents |
WO2005067898A2 (en) | 2004-01-07 | 2005-07-28 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
EP1750668B1 (en) * | 2004-04-13 | 2010-02-17 | Nova Bio-Pharma Technologies Limited | Liquids containing suspended glass particles |
ITMI20040795A1 (it) * | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
BRPI0512326A (pt) | 2004-06-21 | 2008-02-26 | Nektar Therapeutics | composições compreendendo anfotericina b, métodos e sistemas |
WO2006016530A1 (ja) | 2004-08-10 | 2006-02-16 | Translational Research, Ltd. | 速効性でかつ高い吸収性を可能とする経鼻投与用組成物 |
ES2355735T5 (es) | 2004-08-13 | 2014-06-27 | Boehringer Ingelheim International Gmbh | Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso |
EP2431026A1 (en) | 2004-08-13 | 2012-03-21 | Boehringer Ingelheim International GmbH | Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
EA200702049A1 (ru) | 2005-03-23 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиции наночастиц кортикостероидов с антигистаминами |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
WO2006124446A2 (en) * | 2005-05-12 | 2006-11-23 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
AU2006287934B2 (en) | 2005-05-18 | 2012-12-13 | Nektar Therapeutics | Valves, devices, and methods for endobronchial therapy |
PA8675801A1 (es) | 2005-05-19 | 2006-12-07 | Centocor Inc | Anticuerpos anti-mcp-1, composiciones, metodos y usos |
HUE042561T2 (hu) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
JP5113328B2 (ja) * | 2005-11-07 | 2013-01-09 | 田辺三菱製薬株式会社 | エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品 |
WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
WO2007086039A1 (en) * | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | A method of producing porous microparticles |
JP5143131B2 (ja) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
WO2008078730A1 (ja) | 2006-12-26 | 2008-07-03 | Translational Research, Ltd. | 経鼻投与用製剤 |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
MX2009011123A (es) | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
WO2009023803A2 (en) * | 2007-08-15 | 2009-02-19 | Abbott Respiratory Llc | Modulated release formulation for the delivery of one or more medicaments |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
WO2009120619A2 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
PL220269B1 (pl) | 2008-04-21 | 2015-09-30 | Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna | Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego |
EP2285345A1 (en) | 2008-05-15 | 2011-02-23 | Novartis AG | Pulmonary delivery of a fluoroquinolone |
CA2737040C (en) | 2008-09-19 | 2017-05-02 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
AU2009308935B2 (en) | 2008-10-31 | 2015-02-26 | Janssen Biotech, Inc. | Fibronectin type III domain based scaffold compositions, methods and uses |
RU2565438C2 (ru) * | 2008-11-04 | 2015-10-20 | Сипла Лимитед | Фармацевтическая аэрозольная композиция |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
EP2221048A1 (en) | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
EP2413902B1 (en) | 2009-03-18 | 2019-07-17 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
EP2410981B2 (en) | 2009-03-26 | 2020-02-26 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
KR20100123240A (ko) * | 2009-05-15 | 2010-11-24 | 포항공과대학교 산학협력단 | 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법 |
WO2010131486A1 (en) | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
GB2472327B (en) | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
CN102811715A (zh) * | 2009-12-08 | 2012-12-05 | 悉尼大学 | 可吸入制剂 |
US8758824B2 (en) | 2010-08-30 | 2014-06-24 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
US9061352B2 (en) | 2010-08-30 | 2015-06-23 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
PT3470057T (pt) | 2010-09-29 | 2021-12-03 | Pulmatrix Operating Co Inc | Pós secos catiónicos compreendendo sais de magnésio |
CN103228266B (zh) | 2010-10-29 | 2017-11-14 | 健康科学西部大学 | 三元混合物制剂 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
WO2012116362A2 (en) * | 2011-02-25 | 2012-08-30 | The Johns Hopkins University | Chalcone derivatives as nrf2 activators |
GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
CN103687483A (zh) * | 2011-05-17 | 2014-03-26 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
EP2601941A1 (en) | 2011-12-06 | 2013-06-12 | Ludwig-Maximilians-Universität München | Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents |
BR112014025518B1 (pt) | 2012-04-13 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas |
EP2911664B1 (en) | 2012-10-25 | 2019-05-08 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
AU2014228414B2 (en) | 2013-03-15 | 2018-09-13 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
MX2015016102A (es) * | 2013-05-23 | 2016-08-08 | Aztherapies Inc | Metodos para la liberacion de cromolina. |
WO2014207213A1 (en) | 2013-06-28 | 2014-12-31 | Medizinische Universität Innsbruck | Novel inhibitors of protein kinase c epsilon signaling |
CA2928028A1 (en) | 2013-10-22 | 2015-04-30 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
HUE049323T2 (hu) | 2014-02-10 | 2020-09-28 | Respivant Sciences Gmbh | Hízósejt-stabilizálók tüdõbetegség kezelésére |
PT3104853T (pt) | 2014-02-10 | 2020-01-14 | Respivant Sciences Gmbh | Tratamento com estabilizadores de mastócitos para distúrbios sistémicos |
WO2015127315A1 (en) | 2014-02-20 | 2015-08-27 | Otitopic Inc. | Dry powder formulations for inhalation |
EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
CA2991760A1 (en) | 2014-07-31 | 2016-02-04 | Otitopic Inc. | Dry powder formulations for inhalation |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
CN107106641B (zh) | 2014-10-31 | 2021-12-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 粉末制剂 |
JP6395216B2 (ja) * | 2014-11-13 | 2018-09-26 | 国立大学法人大阪大学 | 液体に含まれる超微細バブルの測定方法及びその測定装置 |
WO2016118625A1 (en) | 2015-01-20 | 2016-07-28 | Incarda Therapeutics, Inc. | Unit aerosol doses for anticoagulation |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
US10864190B2 (en) | 2015-04-22 | 2020-12-15 | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH | Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer |
AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
BR122020022602B1 (pt) | 2015-12-04 | 2024-03-05 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica |
WO2017097986A1 (en) | 2015-12-09 | 2017-06-15 | Medizinische Universität Wien | Monomaleimide-functionalized platinum compounds for cancer therapy |
JP2019508383A (ja) | 2016-01-15 | 2019-03-28 | ウニベルジテート ハンブルグUniversitaet Hamburg | O−ラムノシル残基を有するフラボノイド型化合物 |
IL260335B2 (en) | 2016-02-01 | 2023-10-01 | Incarda Therapeutics Inc | Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation |
US10702518B2 (en) | 2016-02-15 | 2020-07-07 | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH | TAF1 inhibitors for the therapy of cancer |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
EP3280414B1 (en) | 2016-04-15 | 2023-08-23 | Oxford University Innovation Limited | Adenosine receptor modulators for the treatment of circadian rhythm disorders |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
WO2018014039A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
BR112019000683A2 (pt) | 2016-07-15 | 2019-04-24 | Poseida Therapeutics Inc | receptores de antígeno quiméricos e métodos para uso |
WO2018045217A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
IL265349B2 (en) | 2016-09-19 | 2023-03-01 | Mexichem Fluor Sa De Cv | Pharmaceutical composition |
MX2019003099A (es) | 2016-09-19 | 2019-06-10 | Mexichem Fluor Sa De Cv | Composicion farmaceutica. |
BR112019005133A2 (pt) | 2016-09-19 | 2019-06-04 | Mexichem Fluor Sa De Cv | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. |
ES2891579T3 (es) | 2016-09-19 | 2022-01-28 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
KR20190059305A (ko) | 2016-09-30 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법 |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
MX2019005443A (es) | 2016-11-14 | 2019-11-21 | Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh | Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer. |
WO2018093841A1 (en) | 2016-11-16 | 2018-05-24 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-il-23 specific antibody |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
EP3621616A4 (en) | 2017-05-10 | 2021-01-13 | InCarda Therapeutics, Inc. | UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION |
AU2018273887B2 (en) | 2017-05-22 | 2022-09-08 | Insmed Incorporated | Lipo-glycopeptide cleavable derivatives and uses thereof |
MX2020000577A (es) | 2017-07-20 | 2020-09-10 | Aztherapies Inc | Formulaciones en polvo de cromolina sodica e ibuprofeno. |
EP3679145A2 (en) | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
WO2019110139A1 (en) | 2017-12-05 | 2019-06-13 | Eth Zurich | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors |
US20210139557A1 (en) | 2017-12-20 | 2021-05-13 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
EP3762015A4 (en) | 2018-03-05 | 2022-04-27 | Janssen Biotech, Inc. | METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY |
WO2019173636A1 (en) | 2018-03-07 | 2019-09-12 | Poseida Therapeutics, Inc. | Cartyrin compositions and methods for use |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
US20210163406A1 (en) | 2018-04-06 | 2021-06-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs |
BR112020020464A2 (pt) | 2018-04-06 | 2021-01-12 | Zilentin AG | Derivados de bumetanida para a terapia da hiperidrose |
JP2021523138A (ja) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク,インコーポレーテツド | Il−23抗体を使用してうつを治療する方法 |
US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
KR20210071943A (ko) | 2018-07-02 | 2021-06-16 | 더 제너럴 하스피탈 코포레이션 | 크로몰린 소듐 및 α-락토스의 분말화된 제형 |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
KR20230148273A (ko) | 2018-09-24 | 2023-10-24 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법 |
CN113395979A (zh) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | 用抗il-23特异性抗体治疗银屑病的安全且有效的方法 |
EP3898614A1 (en) | 2018-12-17 | 2021-10-27 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
CA3125622C (en) | 2019-01-03 | 2023-09-26 | Aqua Yield Operations LLC | Pamam dendrimers for fertilizer delivery |
CN113825765A (zh) | 2019-03-14 | 2021-12-21 | 詹森生物科技公司 | 用于制备抗il12/il23抗体组合物的制造方法 |
US20200331996A1 (en) | 2019-03-18 | 2020-10-22 | Janssen Biotech, Inc. | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody |
US11932585B2 (en) | 2019-04-12 | 2024-03-19 | Aqua Yield Operations LLC | Blended nanoparticle fertilizer delivery |
CN110051868A (zh) * | 2019-04-15 | 2019-07-26 | 宝盈联华(厦门)生物科技有限公司 | 一种带有硅碳岩、礌石粉的橱柜灭菌器 |
JP7404671B2 (ja) * | 2019-06-25 | 2023-12-26 | 株式会社リコー | 多孔質微粒子及びその製造方法、並びに医薬組成物 |
US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
WO2021064141A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
CN114728934A (zh) | 2019-10-02 | 2022-07-08 | 托雷莫治疗股份公司 | 杂环衍生物、药物组合物和它们治疗或改善癌症的用途 |
WO2021074418A1 (en) | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof |
EP4045142A1 (en) | 2019-10-16 | 2022-08-24 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof |
CN115996747A (zh) | 2020-04-14 | 2023-04-21 | 波赛达治疗公司 | 用于治疗癌症的组合物和方法 |
EP4138884A1 (en) | 2020-04-20 | 2023-03-01 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
US20230226057A1 (en) | 2020-06-25 | 2023-07-20 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
EP3939578A1 (en) | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
US20230270669A1 (en) | 2020-09-04 | 2023-08-31 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
EP3964497A1 (en) | 2020-09-04 | 2022-03-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain |
WO2022079290A2 (en) | 2020-10-16 | 2022-04-21 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Cullin ring ubiquitin ligase compounds and uses thereof |
CN112495316B (zh) * | 2020-10-20 | 2021-11-19 | 大连理工大学 | 一种基于亚稳态乳液制备微纳米凝胶微球的方法 |
TW202237102A (zh) * | 2020-12-11 | 2022-10-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 用於肺部遞送的藥物組合物 |
IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody |
WO2022189662A1 (en) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
WO2022190034A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
EP4320109A1 (en) | 2021-04-07 | 2024-02-14 | Tolremo Therapeutics AG | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-IL12/IL23 antibody compositions |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
WO2023203172A1 (en) | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
US20230374122A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1410588A (en) † | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
JPS5134879A (en) * | 1974-09-19 | 1976-03-24 | Eisai Co Ltd | Bishochukuryushinoseizoho |
US4147766A (en) † | 1976-06-09 | 1979-04-03 | Armour Pharmaceutical Company | Macrospherical particles of anti-perspirants |
DE3268533D1 (en) * | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
JP2867404B2 (ja) * | 1983-11-14 | 1999-03-08 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | ドラッグデリバリーのための多孔性ミクロスフェアおよびその製造法 |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
GB8502892D0 (en) * | 1985-02-05 | 1985-03-06 | Sterwin Ag | Aerosol composition |
JPS63500175A (ja) * | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−,インコ−ポレイテツド | リポソ−ム吸入法および吸入システム |
US4950477A (en) † | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
CA2030551C (en) * | 1989-05-01 | 1998-08-25 | Wayne Gombotz | Process for producing small particles of biologically active molecules |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
CA2081474A1 (en) * | 1990-05-08 | 1991-11-09 | Manzer Durrani | Direct spray-dried drug/lipid powder composition |
US5126123A (en) † | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5230884A (en) † | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5304125A (en) † | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
ATE147976T1 (de) * | 1991-01-15 | 1997-02-15 | Hemosphere Inc | Protein nanomatrizen und verfahren zur herstellung |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5182097A (en) † | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
WO1992016192A1 (en) † | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
JPH05500229A (ja) * | 1991-04-12 | 1993-01-21 | 東レ株式会社 | 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法 |
DE69208660T2 (de) * | 1991-06-10 | 1996-07-11 | Schering Corp | Fluorchlorkohlenwasserstoffreie aerosolformulierungen |
DE69232034T2 (de) * | 1991-12-18 | 2002-06-06 | Minnesota Mining & Mfg | Aerosolzusammensetzungen für Arzneimittelsuspensionen |
US5376359A (en) † | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
DE4323636A1 (de) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
US5798091A (en) † | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
EP0711179B2 (en) * | 1993-07-30 | 2010-09-01 | IMCOR Pharmaceutical Co. | Stabilized microbubble compositions for ultrasound |
EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
JPH10506406A (ja) * | 1994-09-29 | 1998-06-23 | アンダリス、リミテッド | 治療用ビヒクルとしての噴霧乾燥させた微細粒子 |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
BR9510510A (pt) * | 1994-12-22 | 1998-07-07 | Astra Ab | Formulação em aerossol farmacêutica uso da mesma e processos para fabricação da mesma para tratamento de um paciente carente de terapia |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
US6136346A (en) * | 1995-04-14 | 2000-10-24 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
EP1444991A1 (en) † | 1995-06-07 | 2004-08-11 | Imarx Pharmaceutical Corp. | Novel targeted compositions for diagnostic and therapeutic use |
US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
ES2236832T3 (es) † | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
AU757153B2 (en) * | 1997-09-29 | 2003-02-06 | Novartis Ag | Stabilized preparations for use in metered dose inhalers |
-
1998
- 1998-09-29 AU AU96772/98A patent/AU757153B2/en not_active Expired
- 1998-09-29 AT AT98954933T patent/ATE239447T1/de not_active IP Right Cessation
- 1998-09-29 DE DE69813853T patent/DE69813853T3/de not_active Expired - Lifetime
- 1998-09-29 JP JP2000513557A patent/JP5372306B2/ja not_active Expired - Lifetime
- 1998-09-29 DE DE69814428T patent/DE69814428T2/de not_active Expired - Lifetime
- 1998-09-29 AU AU10644/99A patent/AU757337C/en not_active Expired
- 1998-09-29 JP JP2000513560A patent/JP2003525842A/ja not_active Withdrawn
- 1998-09-29 JP JP2000513558A patent/JP2001517692A/ja active Pending
- 1998-09-29 CA CA002304819A patent/CA2304819C/en not_active Expired - Lifetime
- 1998-09-29 ES ES98953220T patent/ES2195408T5/es not_active Expired - Lifetime
- 1998-09-29 ES ES98954933T patent/ES2195415T3/es not_active Expired - Lifetime
- 1998-09-29 PL PL98339732A patent/PL195212B1/pl unknown
- 1998-09-29 PT PT98953220T patent/PT1019022E/pt unknown
- 1998-09-29 CA CA002304973A patent/CA2304973C/en not_active Expired - Fee Related
- 1998-09-29 EP EP98950824A patent/EP1019020A1/en not_active Withdrawn
- 1998-09-29 WO PCT/US1998/020615 patent/WO1999016422A1/en active IP Right Grant
- 1998-09-29 WO PCT/US1998/020602 patent/WO1999016419A1/en active Application Filing
- 1998-09-29 AT AT98953220T patent/ATE238035T1/de active
- 1998-09-29 EP EP98954933A patent/EP1019023B1/en not_active Expired - Lifetime
- 1998-09-29 CZ CZ20001115A patent/CZ300758B6/cs not_active IP Right Cessation
- 1998-09-29 KR KR1020007003368A patent/KR100599634B1/ko not_active IP Right Cessation
- 1998-09-29 WO PCT/US1998/020613 patent/WO1999016421A1/en active IP Right Grant
- 1998-09-29 EA EA200000375A patent/EA002562B1/ru not_active IP Right Cessation
- 1998-09-29 KR KR1020007003367A patent/KR100589926B1/ko not_active IP Right Cessation
- 1998-09-29 ES ES98950826T patent/ES2205560T5/es not_active Expired - Lifetime
- 1998-09-29 CA CA002304975A patent/CA2304975C/en not_active Expired - Lifetime
- 1998-09-29 KR KR1020007003401A patent/KR100575070B1/ko not_active IP Right Cessation
- 1998-09-29 EE EEP200000194A patent/EE04628B1/xx unknown
- 1998-09-29 IL IL13512698A patent/IL135126A0/xx active IP Right Grant
- 1998-09-29 ME MEP-41/08A patent/MEP4108A/xx unknown
- 1998-09-29 DK DK98953220.5T patent/DK1019022T4/da active
- 1998-09-29 AU AU11857/99A patent/AU750567B2/en not_active Ceased
- 1998-09-29 AT AT98950826T patent/ATE248583T1/de not_active IP Right Cessation
- 1998-09-29 EP EP98950826A patent/EP1019021B2/en not_active Expired - Lifetime
- 1998-09-29 BR BR9812693-8A patent/BR9812693A/pt not_active Application Discontinuation
- 1998-09-29 RS YUP-183/00A patent/RS50182B/sr unknown
- 1998-09-29 KR KR1020007003416A patent/KR100572171B1/ko not_active IP Right Cessation
- 1998-09-29 EP EP98953220A patent/EP1019022B2/en not_active Expired - Lifetime
- 1998-09-29 AU AU96770/98A patent/AU756693B2/en not_active Ceased
- 1998-09-29 DK DK98950826.2T patent/DK1019021T4/da active
- 1998-09-29 NZ NZ503464A patent/NZ503464A/en not_active IP Right Cessation
- 1998-09-29 SK SK449-2000A patent/SK285068B6/sk not_active IP Right Cessation
- 1998-09-29 CA CA002304820A patent/CA2304820C/en not_active Expired - Fee Related
- 1998-09-29 JP JP2000513559A patent/JP4526702B2/ja not_active Expired - Fee Related
- 1998-09-29 CN CNB98809603XA patent/CN1169520C/zh not_active Expired - Lifetime
- 1998-09-29 TR TR2000/00819T patent/TR200000819T2/xx unknown
- 1998-09-29 EA EA200200036A patent/EA003665B1/ru not_active IP Right Cessation
-
2000
- 2000-03-16 IL IL135126A patent/IL135126A/en not_active IP Right Cessation
- 2000-03-17 BG BG104253A patent/BG64816B1/bg unknown
- 2000-03-24 IS IS5415A patent/IS2154B/is unknown
- 2000-03-28 NO NO20001618A patent/NO340149B1/no not_active IP Right Cessation
- 2000-03-28 HR HR20000175A patent/HRP20000175B1/xx not_active IP Right Cessation
-
2001
- 2001-01-19 HK HK01100524A patent/HK1031680A1/xx not_active IP Right Cessation
-
2009
- 2009-12-01 JP JP2009274003A patent/JP2010047615A/ja not_active Withdrawn
-
2011
- 2011-03-16 JP JP2011058608A patent/JP5739197B2/ja not_active Expired - Lifetime
-
2013
- 2013-07-08 JP JP2013142326A patent/JP6100114B2/ja not_active Expired - Lifetime
- 2013-07-11 JP JP2013145351A patent/JP2013216688A/ja not_active Withdrawn
-
2014
- 2014-06-24 JP JP2014128936A patent/JP6078498B2/ja not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105193773A (zh) * | 2009-05-29 | 2015-12-30 | 珍珠治疗公司 | 活性剂的呼吸递送 |
CN105193773B (zh) * | 2009-05-29 | 2018-12-11 | 珍珠治疗公司 | 活性剂的呼吸递送 |
CN104161731A (zh) * | 2013-05-15 | 2014-11-26 | Cj医药健康株式会社 | 连续工艺的微球制备方法及由此制备的微球 |
US10195149B2 (en) | 2013-05-15 | 2019-02-05 | Cj Healthcare Corporation | Continuous process for preparing microspheres and microspheres prepared thereby |
CN110787134A (zh) * | 2013-05-15 | 2020-02-14 | Cj医药健康株式会社 | 连续工艺的微球制备方法及由此制备的微球 |
CN111700883A (zh) * | 2020-07-23 | 2020-09-25 | 深圳大佛药业股份有限公司 | 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺 |
CN111700883B (zh) * | 2020-07-23 | 2021-04-06 | 深圳大佛药业股份有限公司 | 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1169520C (zh) | 多孔微粒及其使用方法 | |
US6630169B1 (en) | Particulate delivery systems and methods of use | |
US7306787B2 (en) | Engineered particles and methods of use | |
US8246934B2 (en) | Respiratory dispersion for metered dose inhalers comprising perforated microstructures | |
US7628978B2 (en) | Stabilized preparations for use in metered dose inhalers | |
WO2000000215A1 (en) | Particulate delivery systems and methods of use | |
AU760537C (en) | Particulate delivery systems and methods of use | |
AU2006200277B2 (en) | Perforated microparticles and methods of use | |
CN101380309B (zh) | 一种定量吸入气雾剂及其制备方法 | |
MXPA00003103A (en) | Stabilized preparations for use in nebulizers | |
MXPA00003096A (en) | Stabilized preparations for use in metered dose inhalers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NEKTA MEDICINES INC Free format text: FORMER OWNER: INHALE THERAPEUTICS SYSTEMS, INC. Effective date: 20030425 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030425 Address after: California, USA Applicant after: INHALE THERAPEUTIC SYSTEMS, Inc. Address before: California, USA Applicant before: INHALE THERAPEUTIC SYSTEMS, Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1032359 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: NOVARTIS AG Free format text: FORMER OWNER: NOVARTIS INTERNATIONAL AG CO., LTD. Effective date: 20100513 Owner name: NOVARTIS INTERNATIONAL AG CO., LTD. Free format text: FORMER OWNER: NEKTA MEDICINES INC. Effective date: 20100513 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: CALIFORNIA, U.S. TO: BASEL, SWITZERLAND |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100513 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Basel, Switzerland Patentee before: Nova pharmaceuticals Effective date of registration: 20100513 Address after: Basel, Switzerland Patentee after: Nova pharmaceuticals Address before: California, USA Patentee before: INHALE THERAPEUTIC SYSTEMS, Inc. |
|
CX01 | Expiry of patent term |
Granted publication date: 20041006 |
|
CX01 | Expiry of patent term |